Dihexa for Lyme Disease Brain Fog, Neuroborreliosis & PTLDS: Peptidoglycan Persistence, the VLA15 Phase 3 & NICE NG95 (2026 UK Review)

Lyme disease is the most common UK vector-borne illness and one of the most cognitively disabling. The Chief Medical Officer's 2025 infections report places annual UK case numbers at ~1,500 laboratory-confirmed plus 1,000–4,000 additional clinically diagnosed, and a BMJ Open population-based cohort study documented UK incidence climbing from 2.55/100,000 in 2000 to 9.33/100,000 in 2018. An estimated 10–20% of treated patients go on to develop Post-Treatment Lyme Disease Syndrome (PTLDS), in which up to 90% report cognitive symptoms — brain fog, slowed processing, word-finding difficulty and memory lapses that frequently outlast the original infection. The biology is increasingly tractable: the April 2025 Science Translational Medicine paper showed that Borrelia burgdorferi peptidoglycan persists in tissues for weeks after the live organism is killed, sustaining innate immune activation, while neuroimaging cohorts demonstrate microglial activation, elevated TSPO binding and white-matter change in PTLDS. That biology converges on reduced BDNF signalling and impaired hippocampal synaptic plasticity — the same endpoint that Dihexa, a positive modulator of HGF/c-Met synaptogenesis, also reaches. The 23 March 2026 Pfizer/Valneva VLA15 (PF-07307405) Phase 3 VALOR readout (73.2% efficacy) and the NICE NG95 framework provide the policy backdrop. This 2026 UK review walks through tick biology, neuroborreliosis, PTLDS, peptidoglycan persistence, the BDNF-HGF-c-Met case and the evidence hierarchy — with prompt NICE-aligned care first and unlicensed peptides essentially last.

Lyme Disease in the UK in 2026: Where We Actually Stand

Lyme disease, a multisystem infection caused by spirochetes of the Borrelia burgdorferi sensu lato complex (chiefly B. burgdorferi sensu stricto, B. garinii, B. afzelii and B. bavariensis in Europe), is now the most common UK vector-borne illness. The Chief Medical Officer's 2025 annual report on infections, signed off by Professor Sir Chris Whitty, places annual UK incidence at approximately 1,500 laboratory-confirmed cases in England and Wales, with a further 1,000–4,000 clinically diagnosed cases estimated each year on the basis of primary-care coding studies.

The clearest UK incidence dataset is a population-based cohort study published in BMJ Open in 2019 by Cairns and colleagues using the Clinical Practice Research Datalink. Average UK incidence across the study period was 5.18/100,000 person-years, climbing from 2.55/100,000 in 2000 to 9.33/100,000 in 2018 — a roughly threefold rise across two decades. A follow-up 2022 PLOS One analysis linked Lyme diagnosis to a measurable excess of post-infection fatigue at one and three years, consistent with the international PTLDS literature.

Geographic risk is concentrated. The Scottish Highlands and the south of England, the New Forest, parts of Cumbria, Exmoor and the Lake District show repeatedly elevated incidence in UKHSA dashboard data. The picture is changing. The UK Centre for Ecology & Hydrology currently leads a £2 million programme modelling how climate change and woodland expansion are shifting the UK tick distribution. Scotland-specific modelling suggests tick numbers could nearly double by 2080 under a 4°C warming scenario, and UKHSA's May 2026 update confirms tick-borne encephalitis virus (TBEV) is now established at low levels in UK ticks, with three probable or confirmed UK human cases between 2019 and April 2023.

Against that backdrop, the patient-facing question is increasingly familiar from Long COVID, ME/CFS and fibromyalgia: "I had an infection, I had treatment, the bloods are back to normal — why am I still cognitively impaired?" Dihexa is now turning up in chronic-infection forum threads as a candidate procognitive agent for that residual deficit. This article takes the question seriously: does the science support the step, or is the answer the unglamorous one that gets the best evidence base?

Neuroborreliosis vs PTLDS vs "Chronic Lyme": The Important Distinctions

Three overlapping terms are routinely confused in patient-facing discussion. Untangling them matters because they correspond to genuinely different clinical entities with different evidence bases.

Acute Lyme Disease

The early infection itself. Classically begins with erythema migrans (the bullseye rash) within 3–30 days of an infectious tick bite, though up to 30% of patients do not recall a bite and the rash is absent or atypical in a meaningful minority. Systemic features include fever, malaise, fatigue, headache, arthralgia, lymphadenopathy and, in early disseminated disease, cranial nerve palsies (facial nerve in particular), meningitis, radiculopathy, atrioventricular conduction block, multifocal arthritis and skin manifestations. Prompt antibiotics — usually doxycycline 100 mg twice daily for 21 days for adults under NICE NG95, or amoxicillin or ceftriaxone where indicated — reliably clears the infection in the majority and substantially reduces PTLDS risk.

Lyme Neuroborreliosis

The neurological subset of disseminated Lyme infection. The European phenotype (driven principally by B. garinii and B. afzelii) classically presents as Bannwarth syndrome — painful radiculitis, cranial neuritis (frequently bilateral facial palsy) and lymphocytic meningitis — while the North American phenotype tends towards more isolated cranial neuropathy and lymphocytic meningitis. Encephalomyelitis is a rare but reported late manifestation. Diagnosis rests on the combination of compatible neurological features, positive serology and (for definite cases) CSF pleocytosis with intrathecal anti-Borrelia antibody production. Ceftriaxone IV is the usual treatment for definite or probable neuroborreliosis under European Federation of Neurological Societies (EFNS) and NICE NG95 guidance.

Post-Treatment Lyme Disease Syndrome (PTLDS)

A clinically defined post-infectious syndrome characterised by fatigue, widespread musculoskeletal pain, cognitive symptoms and reduced quality of life persisting for at least six months after appropriate antibiotic treatment of documented Lyme disease. The North American IDSA / AAN / ACR case definition requires prior documented Lyme disease, treatment to standard of care, and absence of an alternative explanation. An estimated 10–20% of treated patients develop PTLDS, with cognitive symptoms reported by up to 90% of that cohort. The 2018 PLOS One multimodal neuroimaging study of PTLDS from Johns Hopkins documented microglial activation on TSPO-PET imaging and changes in white-matter integrity that correlated with cognitive performance.

"Chronic Lyme"

A broader, contested term that has historically been used in three quite different ways: as a synonym for PTLDS; for ongoing symptoms attributed to Lyme infection without serological confirmation; and for very prolonged or repeated antibiotic-treatment regimens that fall outside mainstream guidelines. NICE NG95 does not endorse "chronic Lyme" as a free-standing diagnosis. Lyme Disease Action and Lyme Disease UK use the term "ongoing symptoms after Lyme disease" to align with NICE language.

This article focuses on the cognitive symptoms of PTLDS, with brief reference to residual cognitive complaints after treated neuroborreliosis. It is not about acute Lyme — for which prompt antibiotics are the only sensible answer — nor about contested "chronic Lyme" syndromes without supporting evidence of prior infection.

The 2026 Biology of Lyme Brain Fog

Lyme-related cognitive dysfunction is increasingly understood as a multi-mechanism phenomenon driven by persistent innate immune activation, microglial priming and downstream synaptic dysfunction — not by ongoing active infection in the majority of cases.

Persistent Borrelia Peptidoglycan

The most important mechanistic shift in PTLDS biology in the last two years comes from the April 2025 Science Translational Medicine paper by Jutras and colleagues. B. burgdorferi peptidoglycan — the cell-wall scaffold of the spirochete — is structurally unusual and is not cleared by mammalian lysozymes at the rate seen for most other bacteria. In animal models, peptidoglycan accumulated in discrete tissues (including the liver) for weeks after antibiotic killing and continued to drive systemic inflammatory responses consistent with the PTLDS phenotype. The paper reframes PTLDS as a partly antigen-driven syndrome — the live organism is gone, but the structural debris keeps triggering pattern-recognition receptors.

Microglial Activation and Cytokine Drive

The 2018 Frontiers in Microbiology paper by Greenmyer and colleagues showed that primary human microglia respond robustly to B. burgdorferi with upregulation of CCL2, CCL3, CCL5, CXCL10, IL-6 and TNF-α. The downstream phenotype — sustained microglial activation, elevated CSF CXCL13, persistent neuroinflammation — has been demonstrated in PTLDS cohorts using TSPO-PET (microglial translocator protein) imaging and CSF cytokine panels. Microglial activation independently impairs hippocampal LTP and reduces BDNF signalling, providing a mechanistic bridge between immune activation and cognitive symptoms.

Blood-Brain Barrier and Cerebral Blood Flow Changes

Lyme infection and persistent neuroinflammation are associated with measurable disruption of the blood-brain barrier and with altered cerebral blood flow on perfusion imaging. In multimodal neuroimaging cohorts, reduced regional cerebral blood flow correlates with the cognitive symptom burden. These features overlap with the imaging phenotype of Long COVID brain fog and ME/CFS, which makes immune-mediated neurovascular dysfunction one of the strongest unifying biological themes across infection-associated chronic illness.

Anti-Neuronal Antibodies and the Autoimmune Component

A subset of PTLDS patients demonstrate anti-neuronal antibodies that persist after antibiotic treatment. Molecular mimicry between Borrelia outer surface proteins and human myelin and neuronal proteins has been proposed, with parallels in the autoimmune neuroinflammation literature for neuropsychiatric lupus and multiple sclerosis. The clinical implication is that a subset of PTLDS cognitive symptoms may be antibody-mediated rather than purely antigen-driven, and that simple antibiotic re-treatment will not address those cases.

Hippocampal BDNF and Synaptic Plasticity

Sustained microglial activation, cytokine release (IL-6, TNF-α, IL-1β) and oxidative stress all reduce hippocampal BDNF expression and impair long-term potentiation (LTP) at CA1 synapses. The end-state in PTLDS overlaps with the end-state in chemo brain, diabetes-related brain fog and post-stroke cognitive impairment. Reduced hippocampal BDNF / TrkB signalling is the cleanest molecular bridge between persistent neuroinflammation and the cognitive phenotype.

Sleep, Mood, Pain and the Apparent Brain Fog Overlay

PTLDS is rarely a single-domain syndrome. Most patients carry a substantial overlay of fragmented sleep, depression and anxiety, chronic pain and post-exertional malaise — each of which independently reduces cognitive performance. Any honest account of "Lyme brain fog" has to disaggregate the directly immune-driven cognitive deficit from the indirect deficit produced by sleep, mood and pain. This is the most consistent clinical message from specialist Lyme-literate clinical writing.

The BDNF-HGF-c-Met Chain: Where Dihexa Enters the Picture

For the Dihexa-specific question, the most relevant molecular story is the three-way link between hippocampal BDNF, the HGF/c-Met system, and the neuroinflammatory state. Each of these influences synaptic plasticity, and all three converge on the same downstream endpoint: dendritic spine maintenance, synaptic strengthening and circuit integrity.

Hippocampal BDNF, released in an activity-dependent fashion, binds TrkB and drives dendritic spine maturation, LTP, and long-term cognitive plasticity. Independently, HGF/c-Met signalling drives synaptogenesis through the PI-3K/AKT and MAPK pathways — a parallel track that converges on the same cellular outcome. A 2021 Frontiers in Cell and Developmental Biology review details how peak MET expression in cortex coincides with rapid developmental synaptogenesis, with the system remaining active in adult brain and upregulating in response to injury and inflammatory insult.

Dihexa — a small-molecule peptide analogue derived from angiotensin IV — is a positive modulator of the HGF/c-Met pathway. Full molecular detail is on the mechanism of action page. The relevance to PTLDS rests on three points of overlap:

• Synaptogenesis as the direct inverse of cytokine-driven spine loss. Persistent IL-6 and TNF-α elevation reduces hippocampal spine density. Dihexa promotes dendritic spine formation in cell culture within hours of exposure. The end-points are mechanistically symmetrical. The unresolved question is whether spine induction in cell culture translates to measurable cognitive benefit in a chronically inflamed human brain.
• A parallel route to plasticity that does not require BDNF. When BDNF expression is suppressed by sustained inflammation, an upstream pathway that pushes synaptogenesis from a different signalling axis is conceptually interesting. The operative word is conceptually; the clinical data to back up that reasoning in PTLDS do not exist.
• Regional c-Met expression maps onto the PTLDS deficit. The hippocampus, prefrontal cortex and anterior cingulate — the regions most affected by PTLDS-associated cognitive impairment on neuroimaging — are among those with the highest density of c-Met receptors in the adult brain. Pharmacological signal at c-Met therefore lands in an anatomically relevant location.

This is the mechanistic case for considering Dihexa in PTLDS. The rest of this article is about why the shape of the mechanism is not the same as evidence for the intervention — and why the unresolved-inflammation context limits how confidently a synaptogenic peptide can be expected to deliver sustained cognitive benefit.

NICE NG95 First: The Only Evidence-Based Starting Point

Any honest review of Lyme-related cognitive symptoms has to begin with the standard-of-care pathway that addresses the underlying infection. NICE NG95 (Lyme disease: diagnosis and management) sets out a structured pathway for diagnosis, antibiotic treatment, monitoring and review of ongoing symptoms. Several practical points deserve emphasis for cognitive symptoms specifically.

• Prompt antibiotic treatment of acute Lyme dramatically reduces PTLDS risk. The single most influential variable for long-term cognitive outcome is the time interval between infectious tick bite and effective antibiotic exposure. Doxycycline 100 mg twice daily for 21 days is first-line in non-pregnant adults with confirmed or strongly suspected Lyme. Amoxicillin or ceftriaxone are used in specific situations (children, pregnancy, neuroborreliosis, Lyme carditis).
• Erythema migrans alone is sufficient for treatment. NICE NG95 explicitly recommends starting antibiotics on the basis of erythema migrans without waiting for or requiring positive serology. Serology in early Lyme is frequently negative and waiting for it delays antibiotic exposure.
• Two-tier serology for non-EM presentations. Where erythema migrans is absent, the UK pathway uses an ELISA (typically C6-VlsE-based) followed by immunoblot confirmation if positive. Equivocal results trigger repeat testing in 4–6 weeks. False-negative early serology is a known pitfall.
• Specialist input for neurological, cardiac or joint manifestations. Suspected neuroborreliosis, Lyme carditis or persistent monoarthritis should be referred for specialist assessment (infectious diseases, neurology, cardiology or rheumatology as appropriate). CSF examination is appropriate where neuroborreliosis is suspected.
• NICE NG95 recommends against routine prolonged or repeated antibiotics for ongoing symptoms. This is a controversial position in patient communities but is supported by the Klempner NEJM trials and a series of subsequent placebo-controlled RCTs of extended antibiotic regimens for PTLDS — none of which demonstrated sustained benefit and most of which showed substantial harm from line infections, antibiotic toxicity and Clostridioides difficile.
• Look for alternative diagnoses in ongoing symptoms. Iron deficiency, B12 / folate deficiency, vitamin D deficiency, hypothyroidism (see Hashimoto's review), coeliac disease, obstructive sleep apnoea (see OSA review), depression and anxiety are all common and treatable contributors. NICE explicitly recommends screening for these.

For UK patients with ongoing cognitive symptoms after treated Lyme, the right starting point is a structured GP review with NICE NG95 in hand, request for infectious diseases referral where indicated, and screening for the treatable imitators. Experimental peptides are not a substitute for that pathway.

The VLA15 (PF-07307405) Phase 3 VALOR Readout: Prevention is Coming

The largest piece of Lyme news in 2026 is the 23 March 2026 Phase 3 VALOR readout for Pfizer/Valneva's multivalent OspA-based Lyme vaccine candidate VLA15 (now also designated PF-07307405 / LB6V). The trial enrolled approximately 9,400 participants aged 5 years and above across endemic regions in North America and Europe. The headline result: 73.2% efficacy in reducing confirmed Lyme disease cases from 28 days post-dose 4 versus placebo (74.8% from 1-day post-dose 4), with no safety concerns identified at time of analysis.

Pfizer indicated intent to submit a Biologics License Application (BLA) to the FDA and a Marketing Authorisation Application (MAA) to the EMA during 2026, with launch theoretically possible from 2027. UK roll-out would follow MHRA conversion or independent approval and a UK Joint Committee on Vaccination and Immunisation (JCVI) recommendation. Geographic targeting to high-incidence regions (Scottish Highlands, southern England) seems likely on cost-effectiveness grounds, though final policy is not yet decided.

The clinical relevance to PTLDS is partial. A prevention vaccine reduces incidence and therefore the absolute number of new PTLDS cases. It does not treat an already-established PTLDS phenotype. For the cohort of UK patients already living with persistent cognitive symptoms after treated Lyme, the VALOR readout is welcome but not directly helpful. The treatment pathway for established PTLDS still rests on infectious-disease specialist input, screening for treatable contributors, symptom-focused care and rehabilitation, with experimental compounds occupying the same position they did before the vaccine result.

The broader point is that 2026 is shaping into a year of real momentum in Lyme — vaccine, peptidoglycan-persistence biology, advanced neuroimaging in PTLDS, NICE NG95 March 2026 implementation update, and the CMO infections report all landing in close succession. Within that momentum, the case for self-experimentation with unlicensed compounds is, if anything, weaker than it was a year ago.

Lyme-Specific Risks of Dihexa Use in This Population

The general Dihexa safety discussion is on the side effects and risks page. Several risks become more pointed in the context of an infection-associated chronic illness with persistent neuroinflammation.

Synaptogenesis on Top of Unresolved Inflammation

Sustained microglial activation and pro-inflammatory cytokine release reshape the dendritic spine landscape. Pushing synaptogenesis pharmacologically without resolving the upstream inflammatory drive risks producing transient cognitive change that does not consolidate — or, theoretically, dendritic spine populations that are abnormally responsive to ongoing cytokine signalling. The biological case for treating the inflammatory driver first is much stronger than the case for layering a synaptogenic peptide on top.

Masking Treatable Contributors

This is the recurring risk across infection-associated chronic illness. A non-specific lift in perceived cognitive clarity from an unlicensed compound can delay the structured screen for iron deficiency, B12 deficiency, vitamin D deficiency, hypothyroidism, coeliac disease, OSA and depression. These are all genuine, correctable contributors that are cheaply and safely treatable on the NHS. Missing them costs years.

Diagnostic Overshadowing

Patients with documented prior Lyme are at elevated risk of being told that any new symptom is "post-Lyme" without a fresh diagnostic look. New focal neurological signs, persistent headache with red flags, progressive cognitive decline or seizures all warrant a fresh diagnostic workup regardless of Lyme history. Adding an unlicensed peptide to the symptom picture complicates that workup.

HGF/c-Met in Immune Function

HGF/c-Met signalling has documented roles in immune cell migration, T-cell biology and innate immune function. The implications of chronic pharmacological c-Met activation in a population with persistent peptidoglycan-driven innate immune activation are not characterised. This is biological terrain where mechanism-first reasoning is particularly weak.

Baseline Oncology Considerations

The general c-Met / oncology concern that applies to all Dihexa use applies here. HGF/c-Met signalling is oncogenically relevant across multiple tumour types. Patients with a personal or family history of hormone-sensitive cancers, lung, gastric, ovarian or breast cancer, or unresolved suspicious lesions should not consider Dihexa for any indication, including PTLDS.

Strong Placebo Response and Symptom Variability

PTLDS symptoms wax and wane with sleep, infection, stress, weather and seasonal change. Placebo response rates in PTLDS trials run 20–40% for fatigue and similar for cognitive symptoms. Any uncontrolled self-trial of an unlicensed peptide at a symptom peak is structurally biased towards reading regression to the mean as treatment effect.

Mood, Sleep and Symptom Destabilisation

Community reports of Dihexa frequently mention vivid dreams, disturbed sleep and, in a minority, mood changes. In a PTLDS population where sleep is already fragmented and depression and anxiety are frequently co-existing, the margin for destabilisation is smaller than in cognitively-healthy younger users. Any worsening of sleep, mood or fatigue in the first week of a trial should be treated as a stop signal.

The Fosgonimeton Parallel and the Limits of Mechanism

Because no controlled human trial of Dihexa in PTLDS exists, the most informative clinical-stage comparator is fosgonimeton (ATH-1017): a small-molecule positive modulator of the HGF/MET system developed by Athira Pharma. Fosgonimeton is not Dihexa, but it shares the core mechanism of amplifying HGF/c-Met signalling. The full story is on the dedicated fosgonimeton page.

What fosgonimeton brings to the PTLDS question is a sobering lesson in the gap between mechanism and clinical outcome. The active metabolite enhances HGF/MET signalling, demonstrates procognitive effects in animal models of neuroinflammation-driven cognitive impairment (the rodent models most relevant to PTLDS biology) and was well-tolerated in Phase 1 human studies. The Phase 3 LIFT-AD trial in Alzheimer's disease reported out in 2024 and did not meet its primary cognitive endpoint. The programme was subsequently refocused.

The lesson for PTLDS is direct. A well-validated, well-tolerated, mechanistically coherent approach to the HGF/MET system failed to produce a measurable clinical win in a cognitively-impaired population whose pathology overlaps with PTLDS in the inflammation/plasticity domain. Dihexa — whose human data are sparser than fosgonimeton's and whose safety follow-up in chronic use is effectively absent — inherits that cautionary story. Mechanism-first reasoning is seductive; clinical endpoints in cognition are humbling.

Who Should Not Consider Dihexa for Lyme Brain Fog or PTLDS

• Anyone with suspected active or untreated acute Lyme disease — the first call is a GP appointment for NICE NG95-guided antibiotic treatment.
• Anyone with suspected or established neuroborreliosis, Lyme carditis or Lyme arthritis — specialist input is required.
• Anyone with new neurological symptoms (focal weakness, cranial nerve palsy, severe headache with red flags, seizures, sensory loss) — these need fresh diagnostic assessment, not a peptide.
• Anyone with a personal or family history of breast, ovarian, lung, gastric, thyroid or other c-Met-relevant cancers.
• Anyone pregnant, breastfeeding or planning conception.
• Anyone with a diagnosed bipolar or psychotic-spectrum condition.
• Anyone who has not had a structured screen for treatable contributors (ferritin, B12, folate, vitamin D, TSH, coeliac antibodies, fasting glucose / HbA1c, sleep apnoea screening).
• Anyone on multiple licensed medications (antibiotics, immunomodulators, antidepressants, sleep aids) without clinician oversight of an unlicensed addition.
• Anyone whose cognitive symptoms have not been formally characterised — a baseline cognitive assessment is part of distinguishing PTLDS-related cognitive change from alternative diagnoses.

What the Evidence Actually Supports for Lyme Brain Fog and PTLDS in 2026

For balance — and because this is where most patients should start — here is what the 2026 evidence base genuinely supports for cognitive symptoms after treated Lyme.

• NICE NG95-aligned GP assessment. Confirm prior Lyme diagnosis and treatment history. Document current symptom profile. Screen for alternative diagnoses (B12, folate, ferritin, vitamin D, TSH, coeliac, fasting glucose / HbA1c, OSA, mood). The NICE NG95 pathway is the basis for this conversation.
• Infectious disease or neurology referral for persistent neurological symptoms. Patients with persistent focal neurological symptoms, suspected residual neuroborreliosis or unexplained cognitive decline should have specialist review — not a peptide trial.
• Correction of deficiencies. Iron, B12, folate, vitamin D, thyroid optimisation and coeliac screening have the best individual effect sizes for the treatable contributors. They cost little, are NHS-funded and resolve a meaningful fraction of "Lyme brain fog" presentations.
• Treat sleep and mood. Insomnia, OSA, depression and anxiety in PTLDS respond to evidence-based treatment. See OSA review, Dihexa for depression & mood and Dihexa for anxiety & chronic stress.
• Graded physical activity and rehabilitation. Where post-exertional malaise is absent or mild, graded aerobic and resistance activity raises BDNF independently of any pharmacology. Where post-exertional malaise is prominent (more ME/CFS-like), pacing strategies are the appropriate starting point.
• Cognitive rehabilitation and compensatory strategies. External scaffolds (lists, calendars, voice notes), structured cognitive routines and cognitive rehabilitation programmes have replicated effect sizes for post-infection cognitive impairment.
• Vetted patient-facing resources. Lyme Disease Action, Lyme Disease UK, the NHS Lyme disease pages and the UKHSA Lyme dashboard are reliable UK-specific resources.
• Vaccine when available. If VLA15 / PF-07307405 receives EMA/MHRA approval and JCVI recommendation, eligible UK residents in high-risk regions should consider vaccination on standard public-health grounds.
• Tick-bite prevention as primary prevention. Long sleeves and trousers in tick habitat, repellent (DEET 20–50% or icaridin), regular tick checks within 24 hours of exposure, prompt and correct tick removal with fine-tipped tweezers, and seeking GP review for any erythema migrans rash within 30 days of a tick attachment.

If Someone Were Considering It: Practical Realities

This section is descriptive, not prescriptive. There is no validated protocol for Dihexa in PTLDS because there is no trial. What follows is what self-experimenters report and the realities they describe — with caveats that should temper any inference.

• No Lyme-specific dose. Community dosing ranges (covered in the Dihexa dosage guide) were derived from cognitive-enhancement use in healthy younger users. Pharmacokinetics and dose-response in PTLDS populations are not characterised.
• Short trials with clear stop rules. Brief cycles with explicit symptom-tracking endpoints are generally preferred to open-ended use. See the Dihexa Review 2026 for community-reported cycling approaches.
• Avoid complex stacking. Adding Dihexa to an already complex PTLDS regime (antibiotics, antihistamines, low-dose naltrexone, supplements, sleep aids, antidepressants) creates an interaction landscape no one can interpret meaningfully. The general stacking guide cautions explicitly against complex combinations.
• Track and rule out placebo. PTLDS symptoms fluctuate weekly with sleep, stress, infections and weather. Any intervention tried during a symptom-peak week looks effective in the subsequent normal-variance dip. Brief structured symptom diaries covering sleep, mood, cognitive self-ratings, energy and post-exertional malaise are the minimum self-assessment rigour for an unlicensed peptide trial.
• Re-check baseline bloods. Before any trial: FBC, U&E, LFTs, TSH, ferritin, B12, folate, vitamin D, glucose / HbA1c, coeliac antibodies. After: repeat targeted bloods.
• Stop at the first adverse signal. New focal neurological symptoms, worsening fatigue or post-exertional malaise, unexplained pain, mood destabilisation or sleep disruption are all reasons to stop and seek clinical review.

None of this should be read as endorsement. The strongest practical advice for Lyme brain fog and PTLDS in 2026 is the same one that applies before any peptide conversation: complete NICE NG95-aligned assessment, fix the treatable contributors, treat sleep and mood, and engage with specialist input where indicated.

The Bottom Line in 2026

Lyme-related cognitive symptoms are real, biological and increasingly well-understood. The 2025 peptidoglycan-persistence paper, the multimodal PTLDS neuroimaging literature, the microglial activation data and the consistent CSF cytokine signal all converge on a picture of persistent innate immune activation driving sustained hippocampal dysfunction. The dominant first-line intervention — with by far the largest evidence base — is prompt antibiotic treatment of acute Lyme under NICE NG95, with structured infectious-disease specialist input for established PTLDS and rigorous screening for the treatable contributors that cluster with it.

Dihexa, with its direct activation of the HGF/c-Met synaptogenesis pathway, is one of the few small molecules whose mechanism plausibly addresses part of the underlying deficit. The catch is the same as in every other indication on this site: there is no published, registered clinical trial of Dihexa in any tick-borne or infection-associated chronic illness population. The closest clinical-stage relative (fosgonimeton) confirmed feasibility of HGF/MET modulation in humans but missed its Phase 3 cognitive endpoint — in a population whose biology overlaps with PTLDS at the inflammation-plasticity interface. Mechanistic plausibility is necessary but not sufficient.

For the majority of UK patients with cognitive symptoms after treated Lyme, the honest reading of the 2026 evidence is this. NICE NG95 assessment first, antibiotic completion under guideline-aligned care second, structured screening for treatable contributors third, infectious-disease and rehabilitation referral fourth, and research chemicals essentially last — if at all. With the VLA15 Phase 3 readout and the peptidoglycan-persistence story reshaping the field, Lyme medicine is in a moment of real momentum. Self-experimentation with unlicensed peptides is, if anything, harder to justify in this moment, not easier.

Frequently Asked Questions

Related Reading on Dihexa.co.uk

• Dihexa for Long COVID Brain Fog (2026) — the closest infection-associated chronic illness phenotype, with overlapping microglial activation and persistent inflammatory drive.
• Dihexa for PoTS Brain Fog (2026) — autonomic dysfunction (including post-Lyme PoTS) is increasingly recognised; covers the 2025 Adelaide SPECT data and the post-COVID PoTS surge.
• Dihexa for ME/CFS (2026) — another post-infection chronic illness; PTLDS and ME/CFS overlap substantially in symptom profile and likely biology.
• Dihexa for Fibromyalgia & Fibro Fog (2026) — central-sensitisation and chronic-pain overlap with PTLDS.
• Dihexa for Hashimoto's & Hypothyroid Brain Fog (2026) — hypothyroidism is one of the most important treatable imitators of post-Lyme cognitive symptoms.
• Dihexa for Sleep Apnoea Brain Fog (2026) — OSA is over-represented in PTLDS and a key treatable contributor.
• Dihexa for Depression & Mood — the BDNF-synaptogenesis model and its overlap with post-infectious mood symptoms.
• Dihexa for Anxiety & Chronic Stress (2026) — anxiety amplifies perceived cognitive symptoms in PTLDS.
• Dihexa for Lupus Brain Fog & NPSLE (2026) — the antibody-mediated CNS-inflammation parallel.
• Dihexa for Multiple Sclerosis (2026) — the chronic-CNS-inflammation comparator with cognitive change.
• Dihexa for MCI & Brain Aging (2026) — the longer-term cognitive trajectory context.
• Dihexa vs BDNF: What "10 Million Times More Potent" Actually Means — in-depth look at the BDNF mechanism claim.
• Dihexa Review 2026 — effects timeline, oral vs sublingual, cycling.
• Dihexa Stacking Guide — why most stacks need clinician oversight.
• Mechanism of Action — HGF/c-Met, PI-3K/AKT, dendritic spines.
• Side Effects & Risks — the general safety picture.
• UK Legal Status — where Dihexa sits in UK law and MHRA advertising rules.
• Fosgonimeton & Athira — the cautionary Phase 3 story.

External Authoritative Sources Cited

• NICE NG95. Lyme disease: diagnosis and management.
• UK Chief Medical Officer's annual report 2025: infections (Professor Sir Chris Whitty).
• UKHSA Lyme disease dashboard.
• Pfizer / Valneva (23 March 2026). VLA15 (PF-07307405) Phase 3 VALOR positive efficacy readout.
• Jutras BL et al. (Science Translational Medicine, 2025). Persistent B. burgdorferi peptidoglycan.
• Cairns V et al. (BMJ Open, 2019). UK Lyme disease incidence cohort study.
• Geebelen L et al. (PLOS One, 2022). UK Lyme disease incidence and fatigue association.
• Greenmyer JR et al. (Frontiers in Microbiology, 2018). Primary human microglia respond to B. burgdorferi.
• Coughlin JM et al. (PLOS One, 2018). Multimodal neuroimaging in PTLDS.
• Klempner MS et al. (NEJM). Randomized trial of longer-term therapy for symptoms attributed to Lyme disease.
• Fallon BA et al. (Neurology, 2008). Repeated IV antibiotic therapy for Lyme encephalopathy.
• Devoto J et al. (Scientific Reports, 2026). Pilot study of psilocybin in PTLD.
• Desbonnet-Lauquin et al. (Frontiers, 2021). HGF and MET in brain development and neurological disorders.
• Benoist CC et al. (JPET, 2014). Dihexa procognitive effects via HGF/Met.
• UK Centre for Ecology & Hydrology — tick-borne infection climate programme.
• UKHSA (May 2026). Tick-borne encephalitis virus in UK ticks.
• Lyme Disease Action (UK charity).
• Lyme Disease UK.
• NHS — Lyme disease overview.
• Cameron DJ. Post-Treatment Lyme Disease Syndrome (PTLDS) clinical overview.